Furthermore, QRISK3 helps to stratify patients who may require more aggressive monitoring or early initiation of pharmacological interventions, such as GLP-1 receptor agonists, which have demonstrated cardioprotective benefits in individuals with obesity-related metabolic syndrome [48]. This evidence concerns the gene GLP1R and Obesity.